CoChat

Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition

Open access
Zhou, Nan, Liu, Kaili, Sun, Yue, Cao, Ying, Yang, Jing · 2019 · Protein & Cell

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Microglial activation occurs in divergent neuropathological conditions. Such microglial event has the key involvement in the progression of CNS diseases. However, the transcriptional mechanism governing microglial activation remains poorly understood. Here, we investigate the microglial response to traumatic injury-induced neurodegeneration by the 3D fluorescence imaging technique. We show that transcription factors IRF8 and PU.1 are both indispensible for microglial activation, as their specific post-developmental deletion in microglia abolishes the process. Mechanistically, we reveal that IRF8 and PU.1 directly target the gene transcription of each other in a positive feedback to sustain their highly enhanced expression during microglial activation. Moreover, IRF8 and PU.1 dictate the microglial response by cooperatively acting through the composite IRF-ETS motifs that are specifically enriched on microglial activation-related genes. This action of cooperative transcription can be further verified biochemically by the synergetic binding of IRF8 and PU.1 proteins to the composite-motif DNA. Our study has therefore elucidated the central transcriptional mechanism of microglial activation in response to neurodegenerative condition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13238-018-0599-3

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Three-dimensional fluorescence imaging of microglial activation in response to neurodegeneration. (A–E) 3D fluorescence imaging of the mouse optic nerves. (A) The optic nerves before (upper panel) and after (lower panel) the iDISCO procedure. (B–D) The optic nerves of wildtype mice were processed for the whole-tissue immunolabeling of PECAM1 (B), LYVE1 (C) or CD11b (D) and imaged on the lightsheet microscope. (E) The optic nerves of Aldh1l1-GFP transgenic mice were processed for the whole-tissue immunolabeling of GFP and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shown. (F) 3D fluorescence imaging of the traumatic injury-induced neurodegeneration. The wildtype mice were intravitreally injected with the tdTomato-expressing AAV2 and then subjected to optic nerve injury. The control (i.e., uninjured) and injured nerves were processed for the whole-tissue immunolabeling of tdTomato and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shown. (G and H) 3D fluorescence imaging of the glial responses to neurodegeneration. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of Iba1 (G) or Olig2 (H) and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shown
Figure 1 Three-dimensional fluorescence imaging of microglial activation in response to neurodegeneration. (A–E) 3D fluorescence imaging of the mouse optic nerves. (A) The optic nerves before (upper panel) and after (lower panel) the iDISCO procedure. (B–D) The optic nerves of wildtype mice were processed for the whole-tissue immunolabeling of PECAM1 (B), LYVE1 (C) or CD11b (D) and imaged on the lightsheet microscope. (E) The optic nerves of Aldh1l1-GFP transgenic mice were processed for the whole-tissue immunolabeling of GFP and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shown. (F) 3D fluorescence imaging of the traumatic injury-induced neurodegeneration. The wildtype mice were intravitreally injected with the tdTomato-expressing AAV2 and then subjected to optic nerve injury. The control (i.e., uninjured) and injured nerves were processed for the whole-tissue immunolabeling of tdTomato and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shown. (G and H) 3D fluorescence imaging of the glial responses to neurodegeneration. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of Iba1 (G) or Olig2 (H) and imaged on the lightsheet microscope. Representative orthogonal (upper panels) or perspective (lower panels) 3D-projection images of the optic nerves are shownCC BY · PubMed Central
Figure 2 Transcription factor IRF8 acts in microglial activation. (A and B) Microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of CD11b and imaged on the lightsheet microscope. (A) Representative orthogonal 3D-projection images of the injured nerves. (B) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (C–F) Microglial activation in the injured optic nerves does not depend on the chemokine receptors Cx3cr1 and Ccr2. Cx3cr1+/+ vs. Cx3cr1−/− (C and D) or Ccr2+/+ vs. Ccr−/− (E and F) mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of CD11b and imaged on the lightsheet microscope. (C and E) Representative orthogonal 3D-projection images of the injured nerves. (D and F) Density of CD11b+ microglia. n = 4, mean ± SEM. (G and H) Enhanced expression of transcription factor IRF8 in microglial activation. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue co-immunolabeling of IRF8 (red)/CD11b (green) and imaged on the lightsheet microscope. (G) Representative optical sections of the lightsheet imaging (upper panels), orthogonal 3D projections (middle panels) or perspective 3D projections (lower panels) of the optic nerves. (H) Density of IRF8+ nuclei. n = 4, mean ± SEM, *P < 0.01 (Student’s t-test). (I) IRF8 up-regulation in microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 and imaged on the lightsheet microscope. The density of IRF8+ nuclei was quantified. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (J) The IRF-ETS composite motif of IRF8 target sites in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were processed for ChIP-Seq. The de novo analysis of the composite motif of IRF8 target sites was performed. Positions of the IRF motif and ETS motif are highlighted
Figure 2 Transcription factor IRF8 acts in microglial activation. (A and B) Microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of CD11b and imaged on the lightsheet microscope. (A) Representative orthogonal 3D-projection images of the injured nerves. (B) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (C–F) Microglial activation in the injured optic nerves does not depend on the chemokine receptors Cx3cr1 and Ccr2. Cx3cr1+/+ vs. Cx3cr1−/− (C and D) or Ccr2+/+ vs. Ccr−/− (E and F) mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of CD11b and imaged on the lightsheet microscope. (C and E) Representative orthogonal 3D-projection images of the injured nerves. (D and F) Density of CD11b+ microglia. n = 4, mean ± SEM. (G and H) Enhanced expression of transcription factor IRF8 in microglial activation. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue co-immunolabeling of IRF8 (red)/CD11b (green) and imaged on the lightsheet microscope. (G) Representative optical sections of the lightsheet imaging (upper panels), orthogonal 3D projections (middle panels) or perspective 3D projections (lower panels) of the optic nerves. (H) Density of IRF8+ nuclei. n = 4, mean ± SEM, *P < 0.01 (Student’s t-test). (I) IRF8 up-regulation in microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 and imaged on the lightsheet microscope. The density of IRF8+ nuclei was quantified. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (J) The IRF-ETS composite motif of IRF8 target sites in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were processed for ChIP-Seq. The de novo analysis of the composite motif of IRF8 target sites was performed. Positions of the IRF motif and ETS motif are highlightedCC BY · PubMed Central
Figure 3 Transcription factor PU.1 participates in microglial activation. (A) Expression of ETS-family transcription factors in the optic nerves. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the qPCR analysis of ETS-family transcription factors. ND, not detected; n = 4, mean ± SEM. (B and C) Enhanced expression of PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue co-immunolabeling of PU.1 (blue)/CD11b (green) and imaged on the lightsheet microscope. (B) Representative optical sections of the lightsheet imaging (upper panels), orthogonal 3D projections (middle panels) or perspective 3D projections (lower panels) of the optic nerves. (C) Density of PU.1+ nuclei. n = 4, mean ± SEM, *P < 0.01 (Student’s t-test). (D) PU.1 up-regulation in microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of PU.1 and imaged on the lightsheet microscope. The density of PU.1+ nuclei was quantified. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (E) Co-expression of IRF8 and PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were examined by immunohistochemistry for IRF8 and PU.1. (F and G) Cooperative transcription of IRF8 and PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were processed for the ChIP-Seq analysis of PU.1 target sites. (F) Overlap of PU.1 target sites with the IRF8 target sites. (G) The composite motif of PU.1 target sites overlapping with IRF8 target sites was analyzed. Positions of the IRF motif and ETS motif are highlighted
Figure 3 Transcription factor PU.1 participates in microglial activation. (A) Expression of ETS-family transcription factors in the optic nerves. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the qPCR analysis of ETS-family transcription factors. ND, not detected; n = 4, mean ± SEM. (B and C) Enhanced expression of PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue co-immunolabeling of PU.1 (blue)/CD11b (green) and imaged on the lightsheet microscope. (B) Representative optical sections of the lightsheet imaging (upper panels), orthogonal 3D projections (middle panels) or perspective 3D projections (lower panels) of the optic nerves. (C) Density of PU.1+ nuclei. n = 4, mean ± SEM, *P < 0.01 (Student’s t-test). (D) PU.1 up-regulation in microglial activation depends on Sarm1-mediated neurodegeneration. Sarm1+/+ vs. Sarm1−/− mice were subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of PU.1 and imaged on the lightsheet microscope. The density of PU.1+ nuclei was quantified. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (E) Co-expression of IRF8 and PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were examined by immunohistochemistry for IRF8 and PU.1. (F and G) Cooperative transcription of IRF8 and PU.1 in microglial activation. The wildtype mice were subjected to optic nerve injury, and the injured nerves were processed for the ChIP-Seq analysis of PU.1 target sites. (F) Overlap of PU.1 target sites with the IRF8 target sites. (G) The composite motif of PU.1 target sites overlapping with IRF8 target sites was analyzed. Positions of the IRF motif and ETS motif are highlightedCC BY · PubMed Central
Figure 4 Cross-regulation of IRF8 and PU.1 in microglial activation. (A) PU.1 directly targets IRF8 expression in microglial activation. IRF8 and PU.1 target sites at the gene locus of Irf8 are shown. (B and C) PU.1 regulates IRF8 expression. Cx3cr1+/+; Pu.1fl/fl vs. Cx3cr1CreERT2/+; Pu.1fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 or PU.1 and imaged on the lightsheet microscope. (B) Representative orthogonal 3D-projection images of the optic nerves. (C) Density of IRF8+ or PU.1+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (D) IRF8 directly targets PU.1 expression in microglial activation. IRF8 and PU.1 target sites at the UREs of Pu.1 gene locus are shown. (E and F) IRF8 feedback regulates PU.1 expression. Cx3cr1+/+; Irf8fl/fl vs. Cx3cr1CreERT2/+; Irf8fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 or PU.1 and imaged on the lightsheet microscope. (E) Representative orthogonal 3D-projection images of the optic nerves. (F) Density of IRF8+ or PU.1+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test)
Figure 4 Cross-regulation of IRF8 and PU.1 in microglial activation. (A) PU.1 directly targets IRF8 expression in microglial activation. IRF8 and PU.1 target sites at the gene locus of Irf8 are shown. (B and C) PU.1 regulates IRF8 expression. Cx3cr1+/+; Pu.1fl/fl vs. Cx3cr1CreERT2/+; Pu.1fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 or PU.1 and imaged on the lightsheet microscope. (B) Representative orthogonal 3D-projection images of the optic nerves. (C) Density of IRF8+ or PU.1+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (D) IRF8 directly targets PU.1 expression in microglial activation. IRF8 and PU.1 target sites at the UREs of Pu.1 gene locus are shown. (E and F) IRF8 feedback regulates PU.1 expression. Cx3cr1+/+; Irf8fl/fl vs. Cx3cr1CreERT2/+; Irf8fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. The control and injured nerves were processed for the whole-tissue immunolabeling of IRF8 or PU.1 and imaged on the lightsheet microscope. (E) Representative orthogonal 3D-projection images of the optic nerves. (F) Density of IRF8+ or PU.1+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test)CC BY · PubMed Central
Figure 5 IRF8 and PU.1 cooperatively target microglial activation-related genes. (A) IRF8 and PU.1 cooperatively regulate microglial activation-related genes. The genes that contained the IRF8-PU.1 co-target sites were subjected to GO enrichment analysis. Enriched biological processes and signaling pathways are shown. (B) Activation of the NF-κB pathway in microglial activation. Wild-type mice were subjected to optic nerve injury. The control and injured nerves were examined by immunohistochemistry for p-IκBα and CD11b. (C) IRF8 and PU.1 directly target the key signaling components of the NF-κb pathway. IRF8 and PU.1 target sites at the indicated gene loci are shown. The sequence of the DNA probe derived from the IRF8-PU.1 co-target site at each locus is included, with the IRF-ETS composite motif highlighted. (D and E) Biochemical assembly of the ternary complex of the composite-motif DNA with IRF8 and PU.1 proteins. (D) Synergetic binding of IRF8 and PU.1 to the composite-motif DNA, derived from the gene loci of Ripk2, Tak1, Ikbkb or Nfkb1, was examined by EMSA. (E) Supershift of the composite-motif DNA/IRF8/PU.1 ternary complex with anti-IRF8 or anti-PU.1 antibody
Figure 5 IRF8 and PU.1 cooperatively target microglial activation-related genes. (A) IRF8 and PU.1 cooperatively regulate microglial activation-related genes. The genes that contained the IRF8-PU.1 co-target sites were subjected to GO enrichment analysis. Enriched biological processes and signaling pathways are shown. (B) Activation of the NF-κB pathway in microglial activation. Wild-type mice were subjected to optic nerve injury. The control and injured nerves were examined by immunohistochemistry for p-IκBα and CD11b. (C) IRF8 and PU.1 directly target the key signaling components of the NF-κb pathway. IRF8 and PU.1 target sites at the indicated gene loci are shown. The sequence of the DNA probe derived from the IRF8-PU.1 co-target site at each locus is included, with the IRF-ETS composite motif highlighted. (D and E) Biochemical assembly of the ternary complex of the composite-motif DNA with IRF8 and PU.1 proteins. (D) Synergetic binding of IRF8 and PU.1 to the composite-motif DNA, derived from the gene loci of Ripk2, Tak1, Ikbkb or Nfkb1, was examined by EMSA. (E) Supershift of the composite-motif DNA/IRF8/PU.1 ternary complex with anti-IRF8 or anti-PU.1 antibodyCC BY · PubMed Central
Figure 6 Post-developmental IRF8 is required for microglial activation. (A) IRF8 and PU.1 cooperatively target microglial activation-related genes. IRF8 and PU.1 target sites at the indicated gene loci are shown. (B–G) Post-developmental IRF8 is required for microglial activation. Cx3cr1+/+; Irf8fl/fl vs. Cx3cr1CreERT2/+; Irf8fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. (B) Expression levels of the indicated genes in the optic nerves were examined by qPCR analysis. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (C to G) The control and injured nerves were processed for the whole-tissue immunolabeling of Ki67 (C and F) or CD11b (D–G) and imaged on the lightsheet microscope. (C) Representative orthogonal 3D projections of the Ki67-immunolabeled injured nerves. (F) Density of Ki67+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (D) Representative orthogonal (upper panels) or perspective (lower panels) 3D projections of the CD11b-immunolabeled injured nerves. (E) Representative optical sections of the CD11b-immunolabeled injured nerves. (G) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test)
Figure 6 Post-developmental IRF8 is required for microglial activation. (A) IRF8 and PU.1 cooperatively target microglial activation-related genes. IRF8 and PU.1 target sites at the indicated gene loci are shown. (B–G) Post-developmental IRF8 is required for microglial activation. Cx3cr1+/+; Irf8fl/fl vs. Cx3cr1CreERT2/+; Irf8fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. (B) Expression levels of the indicated genes in the optic nerves were examined by qPCR analysis. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (C to G) The control and injured nerves were processed for the whole-tissue immunolabeling of Ki67 (C and F) or CD11b (D–G) and imaged on the lightsheet microscope. (C) Representative orthogonal 3D projections of the Ki67-immunolabeled injured nerves. (F) Density of Ki67+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (D) Representative orthogonal (upper panels) or perspective (lower panels) 3D projections of the CD11b-immunolabeled injured nerves. (E) Representative optical sections of the CD11b-immunolabeled injured nerves. (G) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test)CC BY · PubMed Central
Figure 7 Post-developmental PU.1 is essential for microglial activation. Cx3cr1+/+; Pu.1fl/fl vs. Cx3cr1CreERT2/+; Pu.1fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. (A) Expression levels of the indicated genes in the optic nerves were examined by qPCR analysis. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (B–F) The control and injured nerves were processed for the whole-tissue immunolabeling of Ki67 (B and E) or CD11b (C, D and F) and imaged on the lightsheet microscope. (B) Representative orthogonal 3D projections of the Ki67-immunolabeled injured nerves. (E) Density of Ki67+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (C) Representative orthogonal (upper panels) or perspective (lower panels) 3D projections of the CD11b-immunolabeled injured nerves. (D) Representative optical sections of the CD11b-immunolabeled injured nerves. (F) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test)
Figure 7 Post-developmental PU.1 is essential for microglial activation. Cx3cr1+/+; Pu.1fl/fl vs. Cx3cr1CreERT2/+; Pu.1fl/fl mice were treated with 4-hydroxytamoxifen to induce the Cre-recombinase activity and then subjected to optic nerve injury. (A) Expression levels of the indicated genes in the optic nerves were examined by qPCR analysis. n = 4, mean ± SEM, *P < 0.01 (ANOVA test). (B–F) The control and injured nerves were processed for the whole-tissue immunolabeling of Ki67 (B and E) or CD11b (C, D and F) and imaged on the lightsheet microscope. (B) Representative orthogonal 3D projections of the Ki67-immunolabeled injured nerves. (E) Density of Ki67+ nuclei. n = 3, mean ± SEM, *P < 0.01 (ANOVA test). (C) Representative orthogonal (upper panels) or perspective (lower panels) 3D projections of the CD11b-immunolabeled injured nerves. (D) Representative optical sections of the CD11b-immunolabeled injured nerves. (F) Density of CD11b+ microglia. n = 4, mean ± SEM, *P < 0.01 (ANOVA test)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 83

Metadata

Authors
Zhou, N., Liu, K., Sun, Y., Cao, Y., & Yang, J.
Affiliations
  • Tsinghua University (CN)
  • Peking University (CN)
Corresponding author
Yang, Jing
Venue
Protein & Cell
Published
2018-11-27
Volume
10
Issue
2
Pages
87-103
ISSN
  • 1674-800X (ISSN-L)
  • 1674-8018
OpenAlex
W2902069794
Cited by
81
References
64
Citations by year
2026: 14 · 2025: 16 · 2024: 15 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 8 · 2019: 1
FWCI
2.02
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Protein & Cell (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (31522024, 31771111)
  • Peking University
  • State Key Laboratory of Membrane Biology
  • McGovern Institute for Brain Research, Massachusetts Institute of Technology
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
microglial activation, IRF8, PU.1, transcriptional regulation, neurodegeneration, traumatic brain injury, positive feedback loop, 3D fluorescence imaging
MeSH terms
Interferon Regulatory Factor-8, Proto-Oncogene Protein Spi-1, Animals, Disease Models, Animal, Mice, Inbred C57BL, Optic Nerve, Proto-Oncogene Proteins, Transcription, Genetic, Trans-Activators, Microglia, Neurodegenerative Diseases, Optic Nerve Injuries, Interferon Regulatory Factors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition. https://app.cochat.ai/papers/10.1007/s13238-018-0599-3
The paper
Zhou, N., Liu, K., Sun, Y., Cao, Y., & Yang, J. (2019). Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition. Protein & Cell. https://doi.org/10.1007/s13238-018-0599-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.